These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15993444)

  • 1. Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice.
    Serrano A; Menéndez J; Casarejos MJ; Solano RM; Gallego E; Sánchez M; Mena MA; García de Yebenes J
    Neuropharmacology; 2005 Aug; 49(2):208-19. PubMed ID: 15993444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial dysfunction in parkin null mice: effects of aging.
    Solano RM; Casarejos MJ; Menéndez-Cuervo J; Rodriguez-Navarro JA; García de Yébenes J; Mena MA
    J Neurosci; 2008 Jan; 28(3):598-611. PubMed ID: 18199761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkin deficiency increases the resistance of midbrain neurons and glia to mild proteasome inhibition: the role of autophagy and glutathione homeostasis.
    Casarejos MJ; Solano RM; Rodriguez-Navarro JA; Gómez A; Perucho J; Castaño JG; García de Yébenes J; Mena MA
    J Neurochem; 2009 Sep; 110(5):1523-37. PubMed ID: 19549073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of l-DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal-enriched cultures from parkin knockout and wild-type mice.
    Casarejos MJ; Solano RM; Menéndez J; Rodríguez-Navarro JA; Correa C; García de Yébenes J; Mena MA
    J Neurochem; 2005 Aug; 94(4):1005-14. PubMed ID: 16000163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline.
    Casarejos MJ; Menéndez J; Solano RM; Rodríguez-Navarro JA; García de Yébenes J; Mena MA
    J Neurochem; 2006 May; 97(4):934-46. PubMed ID: 16573651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender differences and estrogen effects in parkin null mice.
    Rodríguez-Navarro JA; Solano RM; Casarejos MJ; Gomez A; Perucho J; de Yébenes JG; Mena MA
    J Neurochem; 2008 Sep; 106(5):2143-57. PubMed ID: 18643794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-motor behavioural impairments in parkin-deficient mice.
    Zhu XR; Maskri L; Herold C; Bader V; Stichel CC; Güntürkün O; Lübbert H
    Eur J Neurosci; 2007 Oct; 26(7):1902-11. PubMed ID: 17883413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of parkin suppression on the behaviour, amyloid processing, and cell survival in APP mutant transgenic mice.
    Perucho J; Casarejos MJ; Rubio I; Rodriguez-Navarro JA; Gómez A; Ampuero I; Rodal I; Solano RM; Carro E; García de Yébenes J; Mena MA
    Exp Neurol; 2010 Jan; 221(1):54-67. PubMed ID: 19815012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midbrain neuronal cultures from parkin mutant mice are resistant to nitric oxide-induced toxicity.
    Solano RM; Menéndez J; Casarejos MJ; Rodríguez-Navarro JA; García de Yébenes J; Mena MA
    Neuropharmacology; 2006 Aug; 51(2):327-40. PubMed ID: 16701721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein.
    Menéndez J; Rodríguez-Navarro JA; Solano RM; Casarejos MJ; Rodal I; Guerrero R; Sánchez MP; Avila J; Mena MA; de Yébenes JG
    Hum Mol Genet; 2006 Jul; 15(13):2045-58. PubMed ID: 16698879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkin null cortical neuronal/glial cultures are resistant to amyloid-β1-42 toxicity: a role for autophagy?
    Solano RM; Casarejos MJ; Gómez A; Perucho J; de Yébenes JG; Mena MA
    J Alzheimers Dis; 2012; 32(1):57-76. PubMed ID: 22785397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice.
    González S; Mena MA; Lastres-Becker I; Serrano A; de Yébenes JG; Ramos JA; Fernández-Ruiz J
    Brain Res; 2005 Jun; 1046(1-2):195-206. PubMed ID: 15882845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality, oxidative stress and tau accumulation during ageing in parkin null mice.
    Rodríguez-Navarro JA; Casarejos MJ; Menéndez J; Solano RM; Rodal I; Gómez A; Yébenes JG; Mena MA
    J Neurochem; 2007 Oct; 103(1):98-114. PubMed ID: 17623040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impairment in consolidation of learned place preference following dopaminergic neurotoxicity in mice is ameliorated by N-acetylcysteine but not D1 and D2 dopamine receptor agonists.
    Achat-Mendes C; Anderson KL; Itzhak Y
    Neuropsychopharmacology; 2007 Mar; 32(3):531-41. PubMed ID: 16760923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flunarizine and cinnarizine-induced parkinsonism: 25 years of de Melo-Souza's syndrome.
    Teive HA; Munhoz RP; Ferraz HB
    Arq Neuropsiquiatr; 2009 Sep; 67(3B):957. PubMed ID: 19838540
    [No Abstract]   [Full Text] [Related]  

  • 16. Iatrogenic parkinsonism: the role of flunarizine and cinnarizine.
    Miguel R; Correia AS; Bugalho P
    J Parkinsons Dis; 2014; 4(4):645-9. PubMed ID: 25125483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function.
    Periquet M; Corti O; Jacquier S; Brice A
    J Neurochem; 2005 Dec; 95(5):1259-76. PubMed ID: 16150055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine.
    Fabiani G; Pastro PC; Froehner C
    Arq Neuropsiquiatr; 2004 Sep; 62(3B):784-8. PubMed ID: 15476069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.